The immunocytokine NHS-IL12 as a potential cancer therapeutic.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 4039112)

Published in Oncotarget on April 15, 2014

Authors

Jonathan Fallon1, Robert Tighe, Giorgio Kradjian, Wilson Guzman, Anna Bernhardt, Berend Neuteboom, Yan Lan, Helen Sabzevari, Jeffrey Schlom, John W Greiner

Author Affiliations

1: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland USA;

Associated clinical trials:

NHS-IL12 for Solid Tumors | NCT01417546

Articles cited by this

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02

Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 10.60

Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med (1993) 8.76

Cloning and expression of murine IL-12. J Immunol (1992) 4.92

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84

Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med (1993) 4.04

Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature (1982) 3.74

Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol (1991) 3.40

Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol (1992) 3.15

Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res (2007) 2.94

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84

Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66

Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol (1992) 2.37

CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol (2003) 2.32

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 2.14

Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09

Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 2.09

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08

Differential regulation of HLA-DR mRNAs and cell surface antigens by interferon. EMBO J (1983) 1.71

Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol (2007) 1.67

Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol (1988) 1.56

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer (2011) 1.39

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer (2011) 1.34

Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res (1999) 1.20

Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res (1998) 1.17

Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res (1989) 1.17

Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther (2007) 1.15

Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res (1996) 1.14

Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment. Oncologist (1996) 1.13

Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol (1994) 1.13

The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J Immunother (2000) 1.11

IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol (2001) 1.10

Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res (1998) 1.09

A novel method for the detection of necrotic lesions in human cancers. Cancer Res (1988) 1.02

Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer (1997) 0.95

Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer (1998) 0.87

Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybrid Hybridomics (2001) 0.86

Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J Immunol (1998) 0.85

Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol (1998) 0.84

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res (2011) 0.81

Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Handb Exp Pharmacol (2008) 0.81

A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol (1999) 0.80

Articles by these authors

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol (2004) 3.11

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 2.91

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res (2004) 2.54

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 2.44

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res (2008) 2.19

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood (2007) 2.01

The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest (2010) 1.98

Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83

A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82

Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81

Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res (2002) 1.77

The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res (2007) 1.65

Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood (2004) 1.62

Prevention of murine erythropoietic protoporphyria-associated skin photosensitivity and liver disease by dermal and hepatic ferrochelatase. J Invest Dermatol (2005) 1.61

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59

Multiple costimulatory modalities enhance CTL avidity. J Immunol (2005) 1.58

Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56

Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) (2011) 1.50

Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res (2005) 1.49

Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res (2003) 1.44

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer (2009) 1.39

Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res (2012) 1.38

Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine (2006) 1.38

Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37

Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res (2006) 1.36

Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol (2003) 1.34

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel (2010) 1.32

Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther (2003) 1.31

A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood (2012) 1.30

Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res (2005) 1.28

Inhibition of TLR3 and TLR4 function and expression in human dendritic cells by helminth parasites. Blood (2008) 1.27

Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26

Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm (2009) 1.26

In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol (2002) 1.24

Physical activity and cancer prevention : pathways and targets for intervention. Sports Med (2008) 1.24

The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res (2005) 1.20

Brugia malayi microfilariae induce cell death in human dendritic cells, inhibit their ability to make IL-12 and IL-10, and reduce their capacity to activate CD4+ T cells. J Immunol (2003) 1.19

Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17

IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells. J Immunol (2008) 1.16

Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res (2013) 1.16

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res (2004) 1.15

Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm (2004) 1.15

Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res (2005) 1.14

The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res (2008) 1.14

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res (2002) 1.14

A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13

Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol (2005) 1.12

Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res (2009) 1.12

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res (2002) 1.10

Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol (2012) 1.09

Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res (2008) 1.09

Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol (2007) 1.07

An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood (2005) 1.06

Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res (2003) 1.05

Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction. J Immunol (2002) 1.05

Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine (2007) 1.04

Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res (2002) 1.04

Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res (2002) 1.03

Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol (2010) 1.02

4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine (2006) 1.02

Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. J Immunol (2013) 1.01

Viral vector-based therapeutic cancer vaccines. Cancer J (2011) 1.00

Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer (2010) 1.00

Translational Research Working Group developmental pathway for immune response modifiers. Clin Cancer Res (2008) 1.00

Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther (2010) 0.99

Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother (2013) 0.98

Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther (2004) 0.98

Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol Immunother (2009) 0.98

Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol (2008) 0.98

Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol Immunother (2002) 0.98

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget (2013) 0.98

Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther (2006) 0.97

Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res (2005) 0.96

Cancer vaccines: preclinical studies and novel strategies. Adv Cancer Res (2006) 0.96